Fibroids are tumors that grow in the muscular lining of the uterus. Uterine fibroids are very common, although most of them cause no symptoms. Fibroids are usually benign not cancerous. If fibroids cause pain, discomfort, difficult menstrual periods, or other complications, they will need to be treated. Also, numerous surgical methods--ranging from minimally invasive to major surgery--can be used for fibroid removal.
Gynaecology Treatment in Brisbane Qld
Norethisterone - Wikipedia
To reduce symptoms associated with uterine fibroids , certain hormone therapies may be suggested by your doctor. These types of medications target hormones that regulate the menstrual cycle, which treats heavy bleeding, pelvic pain, and disorders such as endometriosis; the abnormal tissue growth outside of the uterine lining. While hormone therapy in some instances, can also temporarily shrink fibroids by reducing estrogen levels, they cannot eliminate them completely. Here are a few of the most common hormone medications prescribed for fibroid and fibroid symptoms:. It is used mainly to treat endometriosis, fibrocystic breast disease, stop menstruation, correct anemia and even shrink fibroid tumors by decreasing the number of hormones produced by the ovaries. However, this medication has occasional side effects such as weight gain, dysphoria feelings of depression or uneasiness acne, headaches, unwanted hair growth and a deeper voice.
Fibroids are firm compact tumors that are made of muscle cells. Fibroids can develop in the uterus, in which case they are called uterine fibroids, and the breast. Breast and uterine fibroids are caused by similar issues. However, because they occur in different parts of the body, they cause different symptoms and need to be treated in different ways.
The association between use of oral contraceptives and fibrocystic breast disease was assessed among women aged years in a hospital-based case-control study conducted between November and November in Connecticut. The study groups comprised women with biopsy-proven fibrocystic breast disease and 1, controls who had been admitted, as inpatients or outpatients, to general surgical services. For the premenopausal women, there was no evidence that long-term use of oral contraceptives was associated with a decreased frequency of fibrocystic breast disease among either current or past users. For the postmenopausal women, previous oral contraceptive exposure was associated with an increased occurrence of cystic disease. These findings contradict previous investigations reporting a negative association between oral contraceptive use and the development of fibrocystic breast disease.